4 research outputs found
Оценка воздействия производства эмалированных проводов на атмосферный воздух
В данной работе объектом исследования являются источники загрязнения атмосферы на эмальобмоточном производстве АО "Сибкабель" . Цель работы - оценка воздействия производства эмалированных проводов на атмосферный воздух. Для проведения оценки были изучены нормативно-правовая база проектов нормирования предельно-допустимых выбросов, технология эмалирования проводов, инвентаризационная ведомость источников загрязнения воздуха на производстве. Расчетным путем были получены значения максимально-разовых и валовых выбросов загрязняющих веществ, а также максимальные примесные концентрации вредных веществ в приземном слое атмосферы, которые свидетельствуют о необходимости внесения изменений в имеющийся проект нормативов ПДВ.In this paper, the subject of the study are sources of air pollution at the enamel winding production of JSC "Sibkabel". The aim of the work is to assess the effect of production of enameled wires on atmospheric air.For the assessment, the regulatory and legal framework for the projects for the standardization of maximum permissible emissions, the technology for enameling wires, and the inventories of sources of air pollution in production were studied. Calculations were made for the values ??of maximum-one-time and gross emissions of pollutants, as well as maximum impurity concentrations of harmful substances in the surface layer of the atmosphere, which indicate the need to amend the existing draft MPE standards
Recommended from our members
Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE
The ESSENCE-2 Open-Label Extension study aimed to demonstrate long-term safety, tolerability, and efficacy of a novel water-free, nonpreserved topical cyclosporine 0.1% ophthalmic solution (US brand name VEVYE) for patients with dry eye disease (DED).
This was a Phase 3, prospective, multicenter, open-label, clinical study. All patients received cyclosporine 0.1% ophthalmic solution and dosed each eye twice a day for 52 weeks. Primary safety end points were ocular and nonocular adverse events (AEs). Secondary safety end points included visual acuity, biomicroscopy, intraocular pressure, and dilated fundoscopy. Efficacy end points, such as total corneal fluorescein staining (tCFS) score (National Eye Institute [NEI] Scale), ocular symptoms (visual analog scale [VAS]), and Schirmer tear test, were also assessed.
A total of 202 patients were enrolled from the ESSENCE-2 study. At week 52, 175 patients (86.6%) completed ESSENCE-2 open-label extension. A total of 55 patients (27.5%) reported 74 ocular treatment-emergent adverse events (TEAEs). The most common ocular AE was instillation site pain (6.5%), which was of mild intensity in all cases. Patients showed statistically significant improvements in all prespecified efficacy end points compared with baseline at each visit. Corneal staining improvements were early and stabilized over time while tear production improved continuously. Symptomatology improvement followed these effects with scores reaching a minimum after 1 year of treatment.
The water-free cyclosporine 0.1% ophthalmic solution was safe and well tolerated during long-term use. The results demonstrated sustained 1-year efficacy, in both signs and symptoms of DED, and may help understand short and long-term healing dynamics in a predominant inflammatory DED population